Clinical trial · Interventional
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
NCT04506138CI-TRIAL-00055510unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab | Drug | Camrelizumab | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel for Injection (Albumin Bound) | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Camrelizumab plus Chemotherapy
- interventionNames
- Drug: Camrelizumab
- Drug: Paclitaxel for Injection (Albumin Bound)
- Drug: Carboplatin
Primary outcomes (2)
- measure
- Pathologic complete remission (PCR)
- timeFrame
- 12 weeks
- measure
- Major Pathologic Response (MPR)
- timeFrame
- 12 weeks
Secondary outcomes (2)
- measure
- Overall Survival (OS)
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of thoracic Esophageal squamous cell carcinoma * ECOG performance status 0-1 * Age 18-75 years * Resectable disease, cT2-4aNanyM0 or cT1-3N+M0 * Life expectancy more than 6 months * Use of an effective contraceptive for adults to prevent pregnancy Exclusion Criteria: * Not suitable for surgery * Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC * Prior esophageal, gastric, or gastro-esophageal junction surgery * Esophageal ulcer, esophageal perforation，chest pain（≥middle level） * Pregnant or lactating women
References
Publications (0)
Data not yet available
No reference posted for this study.